Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).

货号（Catalog No.）

CSD00225

通用名INN

Iodine (124I) Girentuximab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).

别名(Alternative names)

124I_WX-G250,124I_cG250

靶点;物种(Specificity target name;species)

CA9[Homo sapiens]

种类(Species)

Chimeric

受体鉴定(Receptor identification)

IgG1-kappa

化学信息

CAS

1011710-99-8

存储条件(Storage)

store at -80°C

Note
For research use only. Not suitable for clinical or therapeutic use.